logo

EVIDENCE • EXPERIENCE • OUTCOMES

INTELLIGENCE BYMDReviewer
Home
About
Peptides
Contact
Back
Pre-approval drug. This compound is in active clinical trials and is not yet FDA-approved. Information here is for situational awareness only and should not be used to inform prescribing decisions.
  • No Preview Available

Retatrutide

PipelinePhase 3PeptideInvestigationalNot approved yet. Being tested in human clinical trials.4.0(1 MD)
Sponsor:
Eli Lilly and Company
Active US trials:
9
Earliest primary completion:
Aug 27, 2026

On this page

  • Synopsis

Trials

  • Clinical trials
  • About this drug

Physicians

  • AI snapshot
  • Physician Buzz
Similar Products
medicine
INVOKANA
medicine
NovoLog
medicine
Novolin
medicine
Nateglinide
Synopsis
Generated with AlphaAI
Product:
Retatrutide
Category:
Indication:
Mechanism:
Safety:
Dosing:
Patient:
Reviews:
No reviews yet
see more
Disclaimer: The synopsis and product information provided on Alpha.MD are derived from openFDA data and are for informational purposes only. This information may not be comprehensive, accurate, or up-to-date. Clinicians should exercise their own professional judgment in interpreting and using this information, and consult the official prescribing information for the most accurate and current details.

Clinical trials (9)

NCTPhaseStatusSponsorPrimary Completion
NCT06260722Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyAug 27, 2026
NCT06859268Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyApr 1, 2028
Status: Investigational
Tested in peopleEvidence: Tested in peopleTested in at least one proper controlled study in people, with results.
NCT06297603Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyOct 26, 2026
NCT07035093Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanySep 1, 2027
NCT07232719Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyJun 1, 2027
NCT07165028Phase 3RECRUITINGEli Lilly and CompanyAug 1, 2030
NCT07357415Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyOct 1, 2028
NCT06383390Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyFeb 1, 2029
NCT06662383Phase 3ACTIVE_NOT_RECRUITINGEli Lilly and CompanyNov 1, 2026

About this drug

Status
Active in clinical trials
Last Refreshed
Nov 13, 2026

Physician Buzz

Pre-Approval Insights
Based on 1 physician input· Limited data — interpret with caution
Retatrutide
Pre-launch sentiment from verified physicians
4.0(1)
Strong interest driven by trial resultsEmerging concern around accessLimited data — sample below 5
Likelihood to Prescribe
4.0/ 575/100

100% rated 4–5 (high intent)

TOP CONCERN
Access

100% of physicians flagged access as a concern

TOP INFLUENCE
Trial results

100% would be most swayed by trial results

E
Endocrinology
New Jersey · Jun 23, 2026
4
For Other

"[No additional comments provided]"

Intent
Likely
Concern
Access
Top influence
Trial results

These are projected insights from pre-approval physician feedback, not real-world post-approval clinical data.

There isn't any reviews posted yet. You can be the first to review the product

AI Snapshot

Pre-Approval Insights
AI-generated executive overview for Retatrutide based on trial data and physician feedback to date.
Clinical highlights
Overall physician sentiment
Key opportunities

No opportunities surfaced from physician feedback yet.

Risks / barriers

No barriers surfaced from physician feedback yet.

Projected adoption
Competitive positioning
Recommended next steps

No action items surfaced yet.

AI-generated based on physician feedback to date and trial data. Projected insights from pre-approval inputs, not real-world post-approval clinical data.